CreatorsPublishersAdvertisers

Rampal

onclive.com

Dr. Rampal on the Importance of Risk Stratification in Myelofibrosis

Raajit K. Rampal, MD, PhD, discusses the importance of risk stratification in myelofibrosis. Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the importance of risk stratification in myelofibrosis. Risk stratification with available scoring systems can inform whether a patient with myelofibrosis will derive a sustained...
CANCER
onclive.com

Dr. Rampal on the Importance of Genomic Testing in Myelofibrosis

Raajit K. Rampal, MD, PhD, discusses the importance of genomic testing in myelofibrosis. Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the importance of genomic testing in myelofibrosis. The JAK inhibitors ruxolitinib (Jakafi) and fedratinib (Inrebic) have transformed the treatment paradigm of myelofibrosis, Rampal says....
RELATED CHANNELS
onclive.com

Dr. Rampal on Symptoms of Disease Progression in Myelofibrosis

Raajit K. Rampal, MD, PhD, discusses symptoms of disease progression in myelofibrosis. Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses symptoms of disease progression in myelofibrosis. No clear definition of disease progression exists in myelofibrosis, but certain factors can be indicative of progression, including patient-reported...
CANCER
onclive.com

Dr. Rampal on Selecting Among Available JAK Inhibitors in Myelofibrosis

Raajit K. Rampal, MD, PhD, discusses considerations for selecting among the JAK inhibitors ruxolitinib and fedratinib in the treatment of patients with myelofibrosis. Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses considerations for selecting among the JAK inhibitors ruxolitinib (Jakafi) and fedratinib (Inrebic) in the treatment of patients with myelofibrosis.
RELATED PEOPLE